Prescribing Acamprosate

Why Acamprosate Matters

Acamprosate is the quiet, safe workhorse of alcohol pharmacotherapy. It won't win a head-to-head shootout on effect size (its benefit over placebo is real but modest), and it demands a punishing three-times-daily schedule. But it occupies a niche no other approved AUD drug fills as cleanly: the abstinence-committed patient with liver disease. Because it is renally excreted and essentially untouched by the liver, acamprosate is the one anti-craving agent you can hand a cirrhotic without checking LFTs or worrying about hepatotoxicity. It carries no boxed warning, no meaningful drug interactions, and no abuse potential.

A word on the evidence, because it is genuinely mixed. European trials in the 1990s and 2000s were largely positive; pooled meta-analyses credit acamprosate with roughly a 14% absolute improvement in the proportion of patients maintaining abstinence (or reduction in return-to-drinking) versus placebo, a number-needed-to-treat in the range of 9 to 12 for maintaining abstinence. But the large U.S. COMBINE trial (JAMA 2006, N=1,383) found acamprosate no better than placebo, and adding it to naltrexone bought nothing over naltrexone alone. The likely reconciliation: the European trials enrolled patients who were detoxified and abstinent at baseline, while COMBINE started patients closer to their last drink. Acamprosate rewards a lead-in period of sobriety. Give it to the right patient at the right moment and it delivers a small, honest edge on abstinence.

Part 1: Indications: Who Is Acamprosate For?

FDA-Approved Use

• Maintenance of abstinence in alcohol dependence (alcohol use disorder), in patients who are abstinent at treatment initiation and receiving psychosocial support. U.S. approval 2004; used in Europe for well over a decade before that.

That approved-indication language is not boilerplate: it is the prescribing strategy. Acamprosate is labeled for patients who have already stopped drinking. It is not a detox drug and not a cut-down drug.

The Ideal Candidate

• Goal is total abstinence (not moderation or harm reduction).
• Already abstinent: ideally through a completed detoxification and a short lead-in sober period (days to a couple of weeks).
• Willing to combine medication with psychosocial support: AA, therapy, or structured counseling. Acamprosate is an adjunct to a recovery program, not a standalone.
• Hepatic disease that rules out other agents: this is where acamprosate shines. Renally cleared, hepatically inert, it is the anti-craving drug of choice in cirrhosis or significant liver dysfunction (provided renal function is intact).
• Wants to avoid the opioid-blocking complications of naltrexone (e.g., a patient on chronic opioid analgesia who cannot take an antagonist).

Who It Is Not For

• The patient still drinking heavily who wants to reduce intake. Acamprosate does not reduce heavy-drinking volume the way naltrexone and topiramate do. Use naltrexone for harm reduction.
• The patient in active withdrawal or mid-detox. Starting acamprosate during detoxification produced worse long-term outcomes than delayed initiation in one open-label study (Kampman 2009). Wait until the withdrawal is over.
• The patient with significant renal impairment (see contraindications): the one place it's dangerous.
• The patient who cannot manage a TID schedule. Six tablets a day, three times daily, is a real adherence barrier. If pill burden will sink adherence, a once-daily or monthly option (oral or injectable naltrexone) may serve better.

Part 2: Before You Start: Workup and Candidacy

Acamprosate is low-maintenance, but two things must be true before you write it.

Check Renal Function

Acamprosate is ~99% renally excreted unchanged. Renal function is the single lab that governs candidacy and dosing. Get a baseline creatinine or estimated creatinine clearance (CrCl) before starting.

• CrCl >50 mL/min: full dose.
• CrCl 30-50 mL/min: reduced dose (see below).
• CrCl <30 mL/min (severe impairment): contraindicated, the drug accumulates.

Confirm the Patient Is Past Withdrawal

Acamprosate is meant to begin as soon as possible after the completion of alcohol withdrawal, once abstinence is achieved, not during acute detox. Confirm the detox window has closed.

What You Do Not Need

• No LFT monitoring: the drug doesn't touch the liver (indeed, hepatic disease is a reason to choose it).
• No ECG.
• No serum drug levels: there's no therapeutic level to follow.
• No baseline CBC or metabolic workup beyond renal function for the drug itself (though a general AUD workup is reasonable clinically).

Part 3: How to Start and Dose

Formulation

• 333 mg delayed-release (enteric-coated) tablets. That's the only formulation. The enteric coating matters: counsel patients to swallow tablets whole, not crush or chew them.

Standard Dosing

• Two 333 mg tablets three times daily: 666 mg TID, 1,998 mg/day (commonly written as "666 mg TID").
• No titration is required: start at the full target dose. There's no ramp-up and no loading; you begin at 666 mg TID from day one (in the renally intact patient).
• Take with or without food, though taking it with meals aids adherence by anchoring the three doses to breakfast, lunch, and dinner.

Renal Dose Adjustment

The Adherence Problem, and How to Fight It

The TID schedule is acamprosate's Achilles' heel. Six tablets spread across the day is a lot to ask of anyone, let alone someone in early recovery. Adherence is the main determinant of whether it works.

Practical countermeasures:

• Anchor doses to meals: "breakfast, lunch, dinner, two pills each" is easier to remember than clock times.
• Use a pill organizer or a phone reminder for the mid-day dose (the one most often missed).
• Set expectations up front: the drug is safe and the benefit is modest, so it only pays off if taken consistently. A skipped dose here and there erodes the whole point.
• Recruit support: the same recovery structure (sponsor, family, program) that supports abstinence can support the pill schedule.

How Long to Treat

Acamprosate is a maintenance medication. In the pivotal trials it was continued for up to a year. There is no defined stop date; continue as long as the patient is benefiting and committed to abstinence. There is no need to taper (see Part 9).

Part 4: Monitoring

Acamprosate is refreshingly light on monitoring.

No LFTs, no ECG, no serum levels are required for the drug. Recheck renal function if the clinical picture changes (new nephrotoxic drug, dehydration, illness) or on a periodic basis in older adults whose GFR drifts down over time.

Part 5: Side Effects and How to Manage Them

Acamprosate's safety and tolerability are its calling card. The side-effect list is short and rarely serious.

Gastrointestinal: Diarrhea (the Main One)

• Diarrhea is the most common and most characteristic adverse effect (roughly 10% of patients, dose-related).
• It is usually mild and self-limited, and rarely leads to discontinuation.

Management:

• Reassure: it typically eases with time.
• Take with food to blunt it.
• Standard antidiarrheal measures (e.g., loperamide PRN) if bothersome.
• Ensure it isn't causing dehydration: in a renally cleared drug, volume depletion matters (see renal caution).

Other, Less Common Effects

• Other GI: nausea, flatulence, abdominal discomfort, generally mild.
• Neuropsychiatric: anxiety, insomnia, and depressive symptoms have been reported. Because untreated AUD itself carries substantial depression and suicide risk, watch mood and suicidality in any patient (attributing a depressive or suicidal signal to "the drug" versus the underlying illness requires clinical judgment; don't ignore it either way).
• Dermatologic: pruritus, rash, uncommon.

What Acamprosate Does Not Do

• No hepatotoxicity: the reason it's the go-to in liver disease.
• No sedation of consequence, no cognitive dulling on the order of topiramate's "Dopamax" effect.
• No abuse potential.
• No disulfiram-like reaction: patients who drink on acamprosate get no aversive reaction (unlike disulfiram). It simply loses its abstinence-supporting effect while they're drinking; you generally continue it through a lapse rather than stopping.

Part 6: Overdose, Toxicity, and Boxed Warnings

• No boxed (black box) warning.
• Overdose experience is limited and reassuringly benign. The main reported feature of acute overdose is diarrhea. There is no known specific antidote; management is supportive.
• Because the drug is renally cleared and not hepatically metabolized, the toxicity concern is not organ damage but accumulation in renal impairment, which is why severe renal disease is a contraindication rather than a monitoring problem.

There is no "toxic level" to chase and no narrow therapeutic window to respect. This is the opposite of a lithium-style drug: the danger isn't a spike in blood level, it's giving it to a kidney that can't clear it.

Part 7: Drug Interactions

This is one of acamprosate's genuine advantages: it has no clinically significant drug interactions.

• No CYP450 involvement: it isn't metabolized by the liver, so it neither induces nor inhibits hepatic enzymes and isn't affected by drugs that do.
• No interaction with naltrexone or disulfiram at the pharmacokinetic level: naltrexone modestly raises acamprosate exposure but with no dose adjustment needed, and the combination is safe (it simply wasn't more effective than naltrexone alone in COMBINE).
• No interaction with alcohol itself: drinking on acamprosate produces no aversive reaction and doesn't alter acamprosate pharmacokinetics.
• No interaction with common psychotropics, antihypertensives, or the drugs a patient with liver disease is likely to be taking.

The one thing to respect: anything that meaningfully reduces renal clearance or causes volume depletion (severe dehydration, acute kidney injury, aggressive diuresis) will raise acamprosate exposure, but this is a renal-function issue, not a classic drug-drug interaction. Keep an eye on renal function when the clinical situation changes.

Part 8: Special Populations

Renal Impairment: The Governing Variable

This is the one population where acamprosate demands care.

• CrCl >50 mL/min: standard 666 mg TID.
• CrCl 30-50 mL/min: reduce to 333 mg TID.
• CrCl <30 mL/min: contraindicated, accumulates; use an alternative.
• Recheck renal function periodically, particularly in older adults, where GFR declines silently.

Hepatic Impairment: Acamprosate's Home Turf

• Safe in mild-to-moderate hepatic impairment; no dose adjustment needed, since the drug bypasses the liver.
• This is precisely why acamprosate is preferred over naltrexone and disulfiram in patients with significant liver disease or cirrhosis, provided renal function is intact. (Note that advanced cirrhosis can produce hepatorenal compromise; if renal function is impaired, the renal rules take over.)

Elderly

• No specific age-based dose change, but renal function declines with age, so check CrCl and dose-adjust accordingly. Many older adults with a "normal" creatinine have a reduced CrCl.
• The TID pill burden and diarrhea (with dehydration risk) warrant a bit more attention in older patients.

Pregnancy and Lactation

• Pregnancy: human data are limited; safety is not established. Reserve for situations where the benefit clearly justifies the risk, in consultation with obstetrics, and remember that untreated heavy alcohol use is itself teratogenic and dangerous. Non-pharmacologic support is first-line.
• Lactation: excretion into human milk and infant effects are not well characterized; generally avoid, or make an individualized risk-benefit decision with pediatrics.

Children and Adolescents

• Not established or FDA-approved in pediatrics. Use is off-label with scant data; not a standard choice.

Part 9: Discontinuation

Acamprosate is one of the easiest psychotropics to stop.

• No withdrawal syndrome, no discontinuation reaction, no taper required. It can be stopped abruptly.
• The only consequence of stopping is loss of its abstinence-supporting effect, which may allow a return to drinking, so discontinuation should be a considered decision, not a default. Continue as long as the patient is abstinent and benefiting; the trials ran up to a year, and longer is reasonable if it's helping.
• You do not need to stop acamprosate if the patient lapses. Because there's no aversive reaction and no danger from drinking on it, the usual move after a slip is to continue the medication, re-engage the psychosocial supports, and reinforce the abstinence goal, not to discontinue.

Part 10: Acamprosate vs the Alternatives

The three FDA-approved AUD medications divide cleanly by goal and patient.

How to choose:

• Liver disease, abstinence goal: acamprosate (renal function permitting).
• Wants to cut down / still drinking / harm-reduction framing: naltrexone (oral or, for adherence, monthly Vivitrol).
• On chronic opioids (can't take an antagonist), abstinence goal: acamprosate.
• Highly motivated, total-abstinence patient with good supervision and no cardiac/hepatic contraindication: disulfiram is reasonable; otherwise acamprosate or naltrexone.
• Severe renal impairment: not acamprosate; consider naltrexone.

On combining agents: the COMBINE trial found acamprosate plus naltrexone was no better than naltrexone alone, so there's no routine reason to stack them. Naltrexone (plus good medical management/counseling) generally carries the stronger evidence base for AUD overall; acamprosate's edge is its niche, the abstinent, liver-compromised, abstinence-committed patient, not superiority head-to-head.

Mechanism: The Short Version

Acamprosate is calcium acetylhomotaurinate, a structural analog of the amino-acid neurotransmitters GABA and taurine. Its precise mechanism remains, in the honest phrasing of the field, "a bit of a mystery."

The prevailing theory: chronic alcohol use leaves the brain in a hyperglutamatergic, GABA-deficient state during early abstinence, an excitatory imbalance that drives the protracted discomfort, dysphoria, and craving of early recovery. Acamprosate is thought to restore the glutamate-GABA balance, most likely by acting as a modulator/weak antagonist at the NMDA glutamate receptor and enhancing GABAergic tone, damping the post-withdrawal hyperexcitability. This is a fundamentally different mechanism from naltrexone (which blocks alcohol's reward): acamprosate instead smooths the neurochemical turbulence of staying abstinent, which fits its clinical role and its dependence on a lead-in abstinence period.

Pharmacokinetically it is unusual: poor oral bioavailability (~11%), which is why the doses are so large; no meaningful hepatic metabolism; ~99% renal excretion of unchanged drug; and a half-life on the order of several hours to a day. The renal-only handling explains everything clinically important about it: the clean interaction profile, the hepatic safety, and the renal contraindication.

Bedside Cheat Sheet